Compare KN & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KN | PHVS |
|---|---|---|
| Founded | 1946 | 2015 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.4B |
| IPO Year | 2013 | 2020 |
| Metric | KN | PHVS |
|---|---|---|
| Price | $37.57 | $31.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 14 |
| Target Price | $43.75 | ★ $57.49 |
| AVG Volume (30 Days) | 567.0K | ★ 788.3K |
| Earning Date | 10-22-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 118.94 | N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $593,200,000.00 | N/A |
| Revenue This Year | $12.37 | N/A |
| Revenue Next Year | $6.90 | N/A |
| P/E Ratio | $337.64 | ★ N/A |
| Revenue Growth | ★ 7.17 | N/A |
| 52 Week Low | $20.57 | $20.65 |
| 52 Week High | $42.93 | $43.25 |
| Indicator | KN | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 52.81 | 38.06 |
| Support Level | $33.56 | $24.95 |
| Resistance Level | $40.08 | $36.36 |
| Average True Range (ATR) | 1.02 | 1.29 |
| MACD | 0.03 | -0.17 |
| Stochastic Oscillator | 39.82 | 22.06 |
Knowles Corp is engaged in the manufacturing of micro-acoustic microphones and balanced armature speakers, audio solutions, high-performance capacitors, and radio frequency filtering products. It operates in two segments; the Precision Devices segment specializes in the design and delivery of high-performance capacitor products and RF solutions; and Medtech & Specialty Audio segment designs and manufactures microphones and balanced armature speakers used in applications. The majority of its revenue comes from the Precision Devices. Geographically, it operates in United States, Asia, Other Americas, Europe and Others, out of which United States generates maximum revenue.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.